How to attend Turner Pope Investments Investor Evening – Monday 13th May 2019

Turner Pope Investments will be holding an Investor Evening this Monday 13th May 2019. With spaces limited it is important you reserve your spot via the email address at bottom.

Venue:
The Saloon, The Ned Hotel (www.thened.com), 27 Poultry, London, EC2R 8AJ – Doors Open at 5.00pm for registration and refreshments with the first presentation to start at 5.30pm.

Presenting on the night, in alphabetical order:

Deltex Medical Group PLC – (LON: DEMG) – Having overseen a dramatic reduction in costs and a swing to operating profit, new Chief Executive Andy Mears will present his plans to grow this unique blood flow monitoring company.

Integumen PLC (LON: SKIN) – Chief Executive Gerry Brandon will present the positive steps taken to refocus Integumen as a virtual microbiology testing company and run through the rationale for the recent acquisition of Rinocloud.

Midatech Pharma PLC (LON: MTPH) – Following a very successful Placing and Open Offer, CFO Nick Robbins-Cherry will explain how the funds are being used developing this novel oncology and rare disease therapy business.

OptiBiotix Health PLC (LON: OPTI) – After a series of positive announcements, we welcome back CEO Stephen O’Hara to provide an update on the Company’s commercial advances in the human microbiome space.

WideCells Group PLC (LON: WDC) – To be renamed Iconic Labs, CEO John Quinlan will provide an overview of the newly-established new media and technology business and its growth strategy.

Spaces are very limited and we will be providing refreshments on the evening

info@turnerpope.com to register interest.

We suggest a smart-casual attire on the evening.

TPI arranges such events to provide Directors and shareholders alike with a forum to engage and network.

Click to view all articles for the EPIC: , , , ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Midatech pharma

    Midatech Pharma closing of $6.0 million Private Placement

    Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, has announced the closing of the Private Placement of 10,344,822 Units initially at an issue price of

    Midatech pharma

    Midatech Pharma pleased with the progress made in H1 2022

    Midatech Pharma Plc (LON:MTPH; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its unaudited interim results for the six months ended 30 June 2022 which will also

    Midatech pharma

    Midatech Pharma MTX110 study to be presented at ISPNO 2022

    Midatech Pharma PLC (LON:MTPH) an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing

    Midatech pharma

    Midatech Pharma granted FDA Fast Track designation for MTX110

    Midatech Pharma PLC (LON:MTPH), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that upon submitting an application to the U.S. Food and Drug Administration, its development programme of MTX110 for the

    Midatech pharma

    Midatech Pharma total gross revenue increases to £0.58m

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its audited preliminary results for the year ended 31 December 2021. 2021 HIGHLIGHTS Operational · In June 2021,

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July

    Midatech pharma

    Midatech Pharma formally opens its new Cardiff headquarters

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at

    Midatech pharma

    Midatech Pharma investor webinar 10th September 2020

    Midatech Pharma plc (LON:MTPH ; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on the 10th September 2020, the